Table 4 Patients with CKD grouped according to plasma aldosterone concentration in the observational study.

From: The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial

 

Q1 n = 28

Q2 n = 29

Q3 n = 27

Q4 n = 28

Q5 n = 29

P

PAC, ng/dL

3.2–8.5

8.6–11.9

12.0–14.4

14.5–19.9

20.5–44.8

P < 0.0001

 

6.20 ± 0.29

10.5 ± 0.20

13.0 ± 0.16

17.1 ± 0.32

26.7 ± 1.22

 

Age

66.3 ± 2.6

64.8 ± 2.2

62.4 ± 2.8

59.8 ± 2.5

61.9 ± 3.1

P = 0.453

Gender, male/female

12/16

10/19

17/10

16/12

18/11

P = 0.0376

Baseline eGFR, ml/min/1.73 m2

62.2 ± 3.7

60.7 ± 3.2

59.3 ± 4.6

49.9 ± 3.1

54.0 ± 3.3

P = 0.098

Urinary protein, g/g creatinine

0.136 ± 0.065

0.192 ± 0.098

0.509 ± 0.281

0.526 ± 0.199

0.406 ± 0.163

P = 0.385

Urinary albumin, mg/g creatinine

83.1 ± 43.5

30.5 ± 10.4

34.3 ± 17.3

141.7 ± 57.1

126.8 ± 52.0

P = 0.168

  1. Urinary markers are normalized by urinary creatinine concentration. Values are expressed as mean ± SEM
  2. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PAC, plasma aldosterone concentration; Q, quartile; SEM, standard error of the mean.
Back to article page